已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

医学 肝细胞癌 队列 内科学 乙型肝炎病毒 胃肠病学 HBeAg 免疫学 肿瘤科 病毒 乙型肝炎表面抗原
作者
Qing-Jing Chen,Kongying Lin,Zhi-Wen Lin,Bing Zhang,Mingqiang Liu,Jianxi Zhang,Qi-Zhen Huang,Kecan Lin,Jinyu Zhang,Fuqun Wei,Peng-Hui You,You Song,Jiang Ya-bin,Hui Zhang,Zhiqing Cheng,Cong-Ren Wang,Yongyi Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:125: 111098-111098 被引量:3
标识
DOI:10.1016/j.intimp.2023.111098
摘要

The efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies (α-PD-1) in advanced hepatocellular carcinoma (HCC) with high hepatitis B virus (HBV) DNA levels (>500 IU/mL) remain unclear. We retrospectively assessed patients from seven medical institutions diagnosed with HBV-related HCC, undergoing treatment with TKIs and α-PD-1 in conjunction with antiviral therapies. Based on HBV-DNA levels, patients were categorized into either high (HHBV-DNA, >500 IU/mL) or low HBV-DNA (LHBV-DNA, ≤500 IU/mL) cohorts Propensity score matching (PSM) was used to minimize baseline imbalance between groups. 149 patients were included, with 66 patients exhibiting HBV-DNA > 500 IU/mL and 83 patients presenting HBV-DNA ≤ 500 IU/mL. Compared with the LHBV-DNA cohort, the HHBV-DNA cohort had a greater incidence of serum HBeAg positivity, tumor diameter ≥ 10 cm, and vascular invasion. Following PSM, 57 individuals were enrolled in each group. Oncological outcomes were comparable between HHBV-DNA and LHBV-DNA cohorts before and after PSM. Before PSM, the median PFS and OS were 6.1 months and 17.5 months in the HHBV-DNA cohort and 6.7 months and 19.3 months in the LHBV-DNA cohort (all P > 0.05). After PSM, the median PFS and OS were 6.0 months and 19.5 months in the HHBV-DNA cohort and 6.0 months and 17.1 months in the LHBV-DNA cohort, respectively (all P > 0.05). Safety profiles were equivalent across cohorts with no fatal incidents reported. Seven patients (4.7 %) had HBV reactivation. 1 (0.7 %) from HHBV-DNA and 6 (4.0 %) from LHBV-DNA (P = 0.134). Only one patient developed HBV-related hepatitis. The effectiveness and safety of TKIs plus α-PD-1 in advanced HCC with HBV-DNA > 500 IU/mL were not compromised in the context of concomitant antiviral therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
5秒前
6秒前
淡然绝山发布了新的文献求助10
7秒前
7秒前
峰feng完成签到 ,获得积分10
8秒前
9秒前
不摇碧莲完成签到 ,获得积分10
11秒前
希希完成签到 ,获得积分10
14秒前
Zbre完成签到,获得积分10
15秒前
桐桐应助人间打气筒采纳,获得10
24秒前
26秒前
搜集达人应助科研通管家采纳,获得10
28秒前
大模型应助科研通管家采纳,获得20
28秒前
科研通AI2S应助科研通管家采纳,获得10
28秒前
28秒前
上官若男应助科研通管家采纳,获得30
28秒前
monster0101完成签到 ,获得积分10
32秒前
32秒前
酷炫的一笑完成签到,获得积分10
33秒前
完美世界应助GL采纳,获得10
39秒前
40秒前
鸭梨发布了新的文献求助10
40秒前
45秒前
咪呀完成签到,获得积分10
46秒前
etheral发布了新的文献求助10
47秒前
风趣小蜜蜂完成签到 ,获得积分10
47秒前
48秒前
优雅愚志完成签到,获得积分10
48秒前
50秒前
木木应助GL采纳,获得10
50秒前
song发布了新的文献求助10
51秒前
54秒前
负责怀莲发布了新的文献求助10
56秒前
Grandir发布了新的文献求助20
57秒前
59秒前
kami完成签到 ,获得积分10
59秒前
赵欣媛完成签到 ,获得积分10
1分钟前
科研通AI5应助Arui采纳,获得10
1分钟前
朴实的热狗完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989949
求助须知:如何正确求助?哪些是违规求助? 3532017
关于积分的说明 11255865
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216